Amneal Pharmaceuticals, Inc.AMRXNASDAQ
Loading
Net Income Growth AcceleratingAccelerating
Percentile Rank100
5Y CAGR+83.6%
Year-over-Year Change
Year-over-year net income growth rate
5Y CAGR
+83.6%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
20.9x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 1380.62% |
| Q3 2025 | -89.43% |
| Q2 2025 | 83.82% |
| Q1 2025 | 139.24% |
| Q4 2024 | -19823.72% |
| Q3 2024 | -102.60% |
| Q2 2024 | 106.54% |
| Q1 2024 | 7.10% |
| Q4 2023 | -1118.89% |
| Q3 2023 | -18.75% |
| Q2 2023 | 271.64% |
| Q1 2023 | -60.24% |
| Q4 2022 | -61.14% |
| Q3 2022 | 97.77% |
| Q2 2022 | -5503.34% |
| Q1 2022 | 66.19% |
| Q4 2021 | -50.51% |
| Q3 2021 | -129.16% |
| Q2 2021 | 116.70% |
| Q1 2021 | 320.81% |
| Q4 2020 | 66.16% |
| Q3 2020 | 25.18% |
| Q2 2020 | -110.43% |
| Q1 2020 | 458.15% |
| Q4 2019 | 87.88% |
| Q3 2019 | -1467.90% |
| Q2 2019 | 64.70% |
| Q1 2019 | -446.09% |
| Q4 2018 | -226.12% |
| Q3 2018 | 103.17% |
| Q2 2018 | -525.82% |
| Q1 2018 | -16.30% |
| Q4 2017 | 129.91% |
| Q3 2017 | -28.48% |
| Q2 2017 | -11.39% |
| Q1 2017 | -21.59% |
| Q4 2016 | 0.00% |